Cell discovery · 2020
A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Zhenghui, Li Ruoxi, Tang Tongke, Ling Dazheng, Wang Manjiong, Xu Dandan, Sun Maoxin, Zheng Lulu, Zhu Feng, Min Hui, Boonhok Rachasak, Ding Yan, Wen Yuhao, Chen Yicong, Li Xiaokang, Chen Yuxi, Liu Taiping, Han Jiping, Miao Jun, Fang Qiang, Cao Yaming, Tang Yun, Cui Jie, Xu Wenyue, Cui Liwang, Zhu Jin, Wong Gary, Li Jian, Jiang Lubin
Аннотация
Although artemisinin combination therapies have succeeded in reducing the global burden of malaria, multidrug resistance of the deadliest malaria parasite, Plasmodium falciparum, is emerging worldwide. Innovative antimalarial drugs that kill all life-cycle stages of malaria parasites are urgently needed. Here, we report the discovery of the compound JX21108 with broad antiplasmodial activity against multiple life-cycle stages of malaria parasites. JX21108 was developed from chemical optimization of quisinostat, a histone deacetylase inhibitor. We identified P. falciparum histone deacetylase 1 (PfHDAC1), an epigenetic regulator essential for parasite growth and invasion, as a molecular target of JX21108. PfHDAC1 knockdown leads to the downregulation of essential parasite genes, which is highly consistent with the transcriptomic changes induced by JX21108 treatment. Collectively, our data support that PfHDAC1 is a potential drug target for overcoming multidrug resistance and that JX21108 treats malaria and blocks parasite transmission simultaneously.